HCV therapy continues to improve

Hepatitis C (HCV) therapy has never been better. The latest data show sustained viral response rates (SVR) of 96 percent across the general population, while tweaks to existing regimens and new agents promise to bring SVRs closer to 100 percent. A panel of experts discussed the prospects for new HCV treatments during an AASLD symposium at DDW 2016.